April 27, 2017
A secondary analysis of DRCR.net Protocol T data demonstrated significant, sustained improvement rates of both nonproliferative and proliferative diabetic retinopathy at 1 and 2 years with all three anti-VEGF agents, low rates of worsening and relatively better performance of aflibercept.
A total of 650 participants were analyzed, 495 with nonproliferative DR and 155 with proliferative DR. Both groups were reduced in number during the course of the study to comply with the study criteria. Improvement and worsening at 1 and 2 years were evaluated by fundus photography according to ETDRS classification levels.